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Abstract
Immune checkpoint inhibitors (ICIs) are effective in treating a variety of malignancies, including 
metastatic bladder cancer. A generally accepted hypothesis suggests that ICIs induce tumor 
regressions by reactivating a population of endogenous tumor-infiltrating lymphocytes (TILs) that 
recognize cancer neoantigens. Although previous studies have identified neoantigen-reactive TILs 
from several types of cancer, no study to date has shown whether or not neoantigen-reactive TILs 
can be found in bladder tumors. To address this, we generated TIL cultures from patients with 
primary bladder cancer and tested their ability to recognize tumor-specific mutations. We found 
that CD4+ TILs from one patient recognized mutated C-terminal binding protein 1 (CTBP1Q277R) 
in an MHC class II-restricted manner. This finding suggests that neoantigen-reactive TILs reside in 
bladder cancer, which may help explain the effectiveness of immune checkpoint blockade in this 
disease, and also provides a rationale for the future use of adoptive T-cell therapy targeting 
neoantigens in bladder cancer.
Introduction
Urothelial carcinoma of the bladder is among the ten most common malignancies 
worldwide, with an estimated 81,190 new cases and 17,240 deaths per year in the United 
States (1). Although the early stage disease, which constitutes the majority of newly 
diagnosed cases, is curable with surgery, there have been no curative treatments for patients 
with metastases, whose 5-year overall survival remains around 15% (2).
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Muscle-invasive bladder cancer (MIBC) is managed with radical cystectomy with 
neoadjuvant cisplatin-based chemotherapy in selected patients. For patients with metastatic 
disease, systemic chemotherapy is the standard of care, with excellent but short-lived 
response rates (2, 3). In addition to these modalities, other therapies have been successfully 
used in treatment of bladder cancer. In high grade non-muscle-invasive bladder cancer 
(NMIBC), intravesical instillation of Bacillus Calmette–Guérin (BCG), an attenuated strain 
of Mycobacterium bovis, was found effective in preventing relapse and progression of 
localized disease after transurethral resection of the bladder tumor (TURBT) (4, 5). 
Although its exact mechanism of action is still unclear, BCG was shown to elicit sustained 
inflammation and recruitment of T lymphocytes to the tumors (6–8).
In recent years, immune checkpoint inhibitors (ICIs) have emerged as an effective 
immunotherapy for several cancer types, including metastatic bladder cancer (9). ICIs are 
monoclonal antibodies that block the function of inhibitory molecules, such as PD-1 
(programmed cell death protein 1) expressed on the surface of T cells, or its inhibitory 
ligand PD-L1 (programmed cell death protein 1 ligand 1) expressed on the surface of tumor 
cells or antigen presenting cells (APCs). Blocking this inhibitory signaling can reactivate T 
cells to induce anti-tumor immune responses and subsequent tumor regression (10). When 
administered to patients with metastatic bladder cancer whose disease progressed after 
standard platinum-based chemotherapy, or who could not tolerate it, ICIs led to durable 
tumor regressions in 15–20% of cases, with up to 11% complete responses in unselected 
patients (11–19). These findings established a pivotal role for ICIs in the treatment of 
metastatic bladder cancer and provided valuable insight into its immunogenicity.
Studies in several cancer types demonstrated a positive correlation between the number of 
tumor mutations and the responses to ICIs (20–23). Next to melanoma and selected types of 
lung cancer, bladder carcinoma exhibits the fourth highest mutation burden among all 
common malignancies, with a median of 155 to 219 mutations per tumor sample across 
several studies (24–27). Among patients with metastatic bladder cancer treated with 
atezolizumab, an anti-PD-L1 antibody, the median tumor mutation number was significantly 
higher in patients who responded to therapy than in those who did not (11, 12, 28). A 
generally accepted hypothesis suggests that malignancies with a higher mutation burden are 
more immunogenic, as they are predicted to present a larger number of neoantigens in the 
MHC-restricted context. Accordingly, ICIs are thought to reactivate tumor-infiltrating 
lymphocytes (TILs), which can recognize these neoantigens and induce tumor regressions 
(20, 21, 29–32).
We have previously shown that neoantigen-reactive TILs can be isolated from metastatic 
melanoma and gastrointestinal cancers, and can lead to durable tumor regressions once in 
vitro expanded and transferred back into the patients (33–37). Although TILs could be 
successfully grown from bladder tumors in our previous study (38), no study to date has 
shown whether or not TILs from bladder tumors can recognize neoantigens. To explore this, 
we first generated polyclonal TIL cultures from five patients with primary bladder tumors 
and co-cultured them with autologous APCs presenting the products of cancer mutations. In 
this study, we describe the isolation and characterization of a neoantigen-reactive TIL 
population from a patient with primary localized urothelial carcinoma of the bladder.
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Five patients with primary localized urothelial carcinoma of the bladder were evaluated and 
treated at the Urologic Oncology Branch at the National Cancer Institute (NCI). All patients 
were enrolled on protocols approved by the NCI Institutional Review Board, and they had 
provided their written informed consent for this study.
Tumor infiltrating lymphocytes
Tumor samples were obtained via TURBT or bladder diverticulectomy. TILs were cultured 
from tumor fragments following a previously described approach (39). Briefly, tumor tissue 
was dissected free of hemorrhagic and necrotic areas and cut into approximately 1×1 mm 
fragments (N=12 or 24), which were then plated individually in 24-well plates and cultured 
in 2 mL of RPMI medium supplemented with 2 mM L-glutamine, 25 mM HEPES, 10 μg/ml 
gentamicin (all from Life Technologies, Carlsbad, CA), 10% human AB serum and 6000 
IU/ml of IL-2 (Prometheus, San Diego, CA) for 6–8 weeks. Medium was replenished twice 
weekly; the wells were split in 1:2 fashion when fully confluent and cryopreserved until 
further use.
Whole exome sequencing
Cancer-specific mutations were identified from tumor samples using whole exome 
sequencing (WES), as described previously (35). Briefly, genomic DNA was first extracted 
from tumors and matched normal blood using a Maxwell instrument (Promega, Madison, 
WI). Next, WES libraries were prepared from genomic DNA (3 μg/sample) using 
SureSelectXT Target Enrichment System coupled with Human All Exon V4 target bait 
(Agilent Technologies, Santa Clara, CA). Libraries from Patient 2 (1st resection) and Patient 
5 were prepared and sequenced on an Illumina HiSeq2000 sequencer (Axeq/Macrogen USA, 
Rockville, MD). Libraries from Patient 1, 3 and 4 were prepared and sequenced in-house on 
a NextSeq 500 desktop sequencer following the manufacturer’s instructions (Illumina, San 
Diego, CA). Sequencing reads were aligned to human genome build 19 using Novoalign 
MPI (http://www.novocraft.com/). Duplicates were marked using Picard’s MarkDuplicates 
tool; in/del realignment and base recalibration was carried out according to the GATK best 
practices workflow (https://www.broadinstitute.org/gatk/). After the data cleanup, pileup 
files were created using samtools mpileup (http://samtools.sourceforge.net). Somatic 
variants were called using Varscan2 (http://varscan.sourceforge.net) according to the 
following criteria: tumor and normal read counts of 10 or greater, variant allele frequency of 
10% or greater, and tumor variant reads of 4 or more. Finally, variants were annotated using 
Annovar (http://annovar.openbioinformatics.org). Tumor-specific mutations for each patient 
are listed in Supplementary Table 1.
Tandem minigene and peptide libraries
TMGs were constructed as described previously (40). For non-synonymous point mutations, 
each mutated amino acid was flanked bilaterally by a sequence encoding 12 wild type (WT) 
amino acids to generate an individual minigene. For each frameshift mutation, a minigene 
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was designed to contain preceding 12 WT amino acids followed by mutated amino acids in 
the new reading frame, which terminated at the new stop codon. Next, up to twelve 
minigenes were linked together to generate tandem minigenes, which were codon-
optimized, synthesized and ligated into a pcDNA3.1 vector using an In-Fusion HD EcoDry 
Cloning Kit (Clontech/Takara, Mountain View, CA). TMG RNA was made by in vitro 
transcription using a HiScribe T7 Quick High Yield RNA Synthesis Kit (New England 
BioLabs, Ipswich, MA). RNA samples were purified using RNeasy Kit (Qiagen, 
Germantown, MD), quantified by spectrophotometry, and stored at −80°C until further use. 
The amino acid sequences of each TMG used in this study are shown in Supplementary 
Table 1.
Crude or HPLC-purified (>90% purity) 25-mer peptides, each encoding a point mutation 
flanked on both sides with 12 WT amino acids, were synthesized by GenScript (Piscataway, 
NJ) as lyophilized power, resuspended in DMSO and stored at −20°C until use.
Antigen presenting cells
To generate Epstein–Barr virus-transformed B (EBV-B) cells, peripheral blood samples were 
collected in Vacutainer CPT (Cell Preparation Tubes with sodium heparin) (BD Bioscience, 
San Jose, CA), followed by isolation of peripheral blood mononuclear cells (PBMCs) 
according to the manufacturer’s instructions. Next, 1 × 107 PBMCs were cultured in 4 ml of 
complete RPMI medium [RPMI 1640 with 10% fetal bovine serum (SAFC, St. Louis, MO) 
and Antibiotic-Antimycotic (Life Technologies)] with addition 1 ml of B95–8 culture 
supernatant containing EBV (ATCC, Manassas, VA) and 0.5 μg/ml of cyclosporine A 
(Sigma Aldrich, St. Louis, MO) for approximately 4–6 weeks. Medium with cyclosporine A 
was replenished as needed. The cells were further expanded in cyclosporine-free medium 
and cryopreserved until future use.
For Patient 2, sufficient PBMCs were obtained via leukapheresis, which enabled us to 
generate autologous dendritic cells (DCs). CD14+ monocytes from PBMC were purified 
using magnetic anti-CD14 microbeads (BD Biosciences, San Jose, CA) and cultured in Petri 
dishes (1 × 107 cells / dish) with complete RPMI medium supplemented with 50 ng/ml GM-
CSF and 20 ng/ml IL- 4 (PeproTech, Rocky Hill, NJ). 5 ml of fresh cytokine-supplemented 
medium was added on day 3. Non-adherent and loosely adherent cells were harvested and 
used for experiments on day 5 or 6.
Library Screening
Recognition of putative neoantigens was assessed by performing overnight co-cultures of T 
cells and APCs, followed by measuring interferon gamma (IFN-γ) production, or 
upregulation of activation markers 4–1BB (CD137) and OX40 (CD134) on the surface of T 
cells.
For peptide library screening, APCs were first incubated with pools of up to 12 individual 
peptides (final concentration ~1 μM per peptide) for 24 hours at 37 °C and then washed 
twice prior to the co-culture. For TMG library screening, APCs were electroporated with 
TMG RNA using Neon Transfection System (Life Technologies) according to the 
manufacturer’s instructions. Briefly, APCs were first washed with PBS and resuspended in 
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R electroporation buffer at 1 × 107 cells/ml. Next, 10 μl of cellular suspension was mixed 
with 1 μg of TMG RNA, and electroporated using 1500 V × 30 ms × 1 pulse for DCs or 
1600 V × 10 ms × 3 pulses for EBV-B cells. Electroporated cells were rested in Opti-MEM 
(Life Technologies) for 1 hour at 37 °C prior to the co-culture.
Cryopreserved TILs or TCR-transduced T cells were first rested overnight in complete AIM 
V [AIM V CTS medium (Life Technologies) with 5% human AB serum (Valley Biomedical, 
Winchester, VA) and Antibiotic-Antimycotic] supplemented with IL-2 (6000 IU/ml for TILs 
and 1200 IU/ml for TCR-transduced T cells). The following day, cells were washed twice to 
remove excess IL-2 and plated (1 × 105 cells/well) with equal number of APCs into U-
bottom 96-well plates (for subsequent ELISA and flow cytometry) or MultiScreen-IP filter 
plates (for ELISPOT). Co-cultures were incubated overnight at 37 °C and 5% CO2. Cell 
Stimulation Cocktail [phorbol 12-myristate 13-acetate (PMA) and ionomycin] (Affymetrix, 
San Diego, CA) was used as a positive control in 1:1000 v/v ratio.
Detection of cytokines in lymphocyte co-culture assays
The secretion of IFN-γ, GM-CSF, TNF-α, IL-2 and IL-4 from T cells after overnight co-
cultures was measured by enzyme-linked immunosorbent assays (ELISA). Briefly, co-
culture plates were first spun at 300 × g for 2 minutes at room temperature, followed by 
measuring cytokine concentration in the co-culture supernatants using respective ELISA kits 
(all from ThermoFisher Scientific, Waltham, MA). Cell pellets were resuspended in PBS 
with 0.5% FBS and set aside for flow cytometric analysis. ELISA plates were read on 
Spectramax 190 microplate spectrophotometer (Molecular Devices, Sunnyvale, CA) and 
analyzed using SoftMax Pro 6.2.2 software (Molecular Devices).
Flow cytometric analysis
For all experiments, cells were stained with antibodies diluted in PBS/0.5% FBS in 1:50 
V/V ratio at 4°C for 30 minutes. The following antibodies were used: CD4 (clone SK3), 
CD8 (clone SK1), CD134 (OX40, clone ACT35), CD137 (4-1BB, clone 4B4-1), and anti-
mouse TCRβ Chain (clone H57-597) (BD Biosciences, San Jose, CA). Flow cytometric 
analysis was performed on FACS Canto I cell analyzer (BD Biosciences). Data was analyzed 
using FlowJo 10.2 software (TreeStar, Ashland, OR).
Identification and synthesis of T-cell receptors (TCRs)
To isolate TCR sequences, a recently described single-cell approach was used, with some 
modifications (41). Briefly, 1 × 106 TILs were co-cultured overnight with 1 × 106 EBV-B 
cells pulsed with HPLC-purified CTBP1Q277R 25-mer peptide. The following morning, 
stimulated T-cells were sorted based on 4–1BB upregulation using the FACS Aria Cell 
Sorter (BD Biosciences). Sorted 4–1BB+ T cells were subjected to automated single-cell 
RNA-sequencing sample preparation using the Fluidigm C1 platform (Fluidigm, San 
Francisco, CA), following the manufacturer’s instruction. Single-cell RNA-seq was 
performed using Illumina MiSeq system (Illumina). The paired full-length TCRα/β 
sequences were identified using an in-house software.
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To synthesize the identified TCR, TCRα/β constant regions were replaced with modified 
mouse TCRα/β constant regions to enhance TCR pairing and surface expression (42–44). 
TCRα and β chains were linked with a furin SGSG P2A linker, and then synthesized and 
cloned into a MSGV retroviral vector (45).
Generation of TCR-transduced T cells
Retroviral transduction of TCR into donor T cells has been described previously (46). 
Briefly, on day 1, 293GP cells were plated (1 × 106/well) in poly-D-lysine-coated 6-well 
plate (Corning, Tewksbury, MA). On day 2, each well was transfected with 1.5 μg 
pMSGV8-TCR and 0.75 μg pRD114 (VSV-G) using Lipofectamine 2000 Transfection 
Reagent (Life Technologies). Simultaneously, ~1–3 × 108 donor PBMCs were stimulated 
with 50 ng/ml anti-CD3 (eBioscience, San Diego, CA) and 1200 IU/ml of IL-2 in a tissue 
culture flask. Where indicated, PBMCs were enriched for CD4+ T cells by depleting CD8+ 
T cells using anti-CD8 magnetic beads (BD Biosciences, San Jose, CA) and then processed 
in the same way. On day 3, retrovirus-containing supernatants from 293GP cells were 
harvested and spinoculated onto a RetroNectin (Takara Bio USA, Mountain View, CA)-
coated 6-well plate at 2000 × g for 2 hours at room temperature, while the 293GP cells were 
re-fed with fresh media and set aside for an additional 24-hour incubation. Following the 
removal of unbound supernatant, spinoculated plate was seeded with donor PBMCs (1 × 106 
cells/well), centrifuged at 1000 × g for 10 minutes and incubated overnight at 37°C. On day 
4, supernatants from 293GP were re-harvested and spinoculated onto a new RetroNectin-
coated plate, which was used to re-transduce PBMCs from the previous day following the 
same protocol. Transduced cells were then cultured in complete AIM V medium 
supplemented with 1200 IU/ml of IL-2 for additional 5 days. The TCR-transduced T cells 
were cryopreserved until further use. When using CD8-depleted PBMCs, pure CD4+ 
transduced T cells were obtained at the end of the process, as described previously (47).
Determination of HLA restriction element
Relevant HLA alleles identified from tumor WES were synthesized and cloned into 
pcDNA3.1 vector (GeneOracle, Santa Clara, CA). Next, COS-7 cells were plated (2.5 × 104 
cells/well) in a flat-bottom 96-well plate and co-transfected the following day with 
combinations of individual MHC plasmids (150 ng/well each) using Lipofectamine 2000 
transfection reagent (0.5 μl/well). The next day, transfected cells were pulsed with WT and 
mutant 25-mer peptide for 2 hours, washed twice in complete RPMI, and co-cultured 
overnight with 1 × 105/well of TCR-transduced T cells. IFN-γ production was assessed by 
ELISA, as described above.
Multi-cytokine analysis
Supernatants from overnight TIL or TCR-transduced donor T cell co-cultures were analyzed 
using a multiplex sandwich immunoassay named U-PLEX (Meso Scale Diagnostics, 
Rockville, MD), in accordance with the manufacturer’s instructions. The assay was 
customized to allow simultaneous detection of IFN-γ, TNF-α, IL-2, IL-4, IL-5, IL-10, IL-13 
and GM-CSF.
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Tissue sections from formalin-fixed, paraffin-embedded (FFPE) TURBT specimens were 
stained with H&E and immune-stained with the following antibodies: CD3 (clone 2GV6), 
CD4 (clone SP35), CD8 (clone SP57) (Ventana, Tucson, AZ), MHC class I (clone HC-10) 
(kindly provided by Dr. Soldano Ferrone), and HLA-DR (clone TAL.1B5) (Dako, 
Carpinteria, CA). Staining was performed at the Laboratory of Pathology (NCI); stained 
sections were examined by a certified pathologist who was blinded to the results of 
neoantigen screening.
Statistical analysis
Statistical analyses were performed on GraphPad Prism 7.0 software (GraphPad Software, 
La Jolla, CA). When applicable, data were expressed as mean ± standard deviation (SD).
Results
In this study, we tested TILs from five patients who had primary localized urothelial 
carcinoma of the bladder, including low- and high-grade NMIBC and high-grade MIBC, and 
who underwent stage-based treatment with TURBT ± BCG at the NIH Clinical Center. The 
size of resected tumor specimens, obtained mostly via TURBT that yielded small slices of 
tumors, was only several mm3 for all five patients. TIL growth occurred slowly and was seen 
only in a fraction of cultured tumor fragments. The number of tumor-specific mutations on 
WES ranged between 120 and 232, which was consistent with previous reports in bladder 
cancer (24, 25). Patient information, tumor characteristics and IHC results are summarized 
in Table 1; CD8 vs CD4 composition of individual TIL cultures is shown in Supplementary 
Figure 1.
Patient 1, a 75-year-old man whose cancer was previously treated with TURBT and 
intravesical BCG at an outside institution, presented to the NIH with relapsed localized 
disease and underwent another TURBT. WES of the fresh tumor sample led to identification 
of 120 unique mutations, which were incorporated into 11 individual TMGs (Supplementary 
Table 1). Simultaneously, four TIL cultures (F1 - F4) grew out of 12 plated tumor fragments. 
We performed overnight co-cultures with TILs and autologous EBV-B cells electroporated 
with 11 individual TMGs, and then assessed T cell reactivity by performing IFN-γ ELISA. 
As indicated in Figure 1A, marked IFN-γ production was detected when TIL fragment 3 
(F3) was co-cultured with TMG2. To determine which TMG2-encoded mutation was the 
candidate neoantigen, F3 TILs were co-cultured with EBV-B cells pulsed with individual 
mutated 25-mer peptides encoded in TMG2. As indicated in Figure 1B, only a mutated 
peptide harboring a single glutamine-to-arginine substitution in C-terminal binding protein-1 
(CTBP1Q277R) elicited IFN-γ production from F3 TILs. Moreover, when compared to its 
wild type counterpart, HPLC-purified mutant CTBP1 elicited significantly increased 
production of IFN-γ, TNF-α, IL-5, IL-13 and GM-CSF, and slightly increased production of 
IL-4 and IL-10, as measured by a multiplex assay (Figure 1C). The increased production of 
IFN-γ, GM-CSF and TNF-α was further confirmed by ELISA (Supplementary Figure 2).
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To isolate TCRs that recognized the CTBP1Q277R epitope, F3 TILs were co-cultured 
overnight with autologous EBV-B cells pulsed with CTBP1Q277R 25-mer peptide, and then 
analyzed by FACS for upregulation of 4–1BB. As indicated in Figure 2A, 3.1% of cells, all 
phenotypically CD4+ T lymphocytes, upregulated 4–1BB when co-cultured with 
CTBP1Q277R peptide, in comparison to 0.3% in the DMSO control. These CD4+ 4–1BB+ 
TILs were sorted and subjected to single-cell RNA-seq analysis, which identified a single 
TCR sequence (Figure 2B). This TCR was then synthesized, cloned into a MSGV plasmid 
and transduced into PBMCs from two unrelated donors with greater than 50% efficiency 
(Figure 2C). The TCR-transduced T cells were then co-cultured with autologous EBV-B 
cells pulsed with either CTBP1Q277R 25-mer peptide or the corresponding WT control, 
followed by assessment of IFN-γ production by ELISA. As indicated in Figure 2D, 
CTBP1Q277R -TCR-transduced T cells from both donors recognized CTBP1Q277R peptide in 
a dose-dependent manner, whereas there was no reactivity against the WT peptide. 
Moreover, in a multiplex assay using CTBP1Q277R -TCR transduced CD4+ T cells, 
stimulation with mutated 25-mer peptide elicited increased production of TNF-α, IL-2, IL-4, 
IL-5, IL-10, IL-13 and GM-CSF in comparison to the wild type peptide (Figure 2E). The 
increased production of GM-CSF, TNF-α, IL-2 and IL-4 was further confirmed by ELISA 
(Supplementary Figure 3).
To determine the minimal epitope recognized by CTBP1Q277R-TCR, TCR-transduced T 
cells were co-cultured with autologous EBV-B cells pulsed with serial truncations of 
CTBP1Q277R 25-mer peptide. As indicated in Figure 3A, the loss of amino acids delineating 
the 13-mer (KALARALKEGRIR) resulted in significantly decreased IFN-γ production. We 
then synthetized this mutated 13-mer peptide and its WT counterpart, alongside several 
serial truncations of each peptide, and used them in co-cultures with transduced T cells. As 
shown in Figure 3B, the strongest IFN-γ production was detected when T cells were co-
cultured with the mutated 13-mer, with no response to any of the WT peptides, suggesting 
that this peptide was likely the minimal epitope recognized by CTBP1Q277R-TCR.
To determine the MHC class II-restriction element for CTBP1Q277R-TCR, COS-7 cells were 
transfected with pairs of plasmids encoding the following MHC class II molecules identified 
from this patient’s tumor WES data: DPA1*01:03:01, DPB1*03:01:01, DPB1*04:01:01, 
DQA1*01:02:01, DQA1*05:01:01, DQB1*02:01:01, DQB1*06:04:01, DRB1*03:01:01, 
DRB1*13:02:01, DBR3*01:01:02, DRB3*03:01:01, DRB4*01:01:01. Next, transfected 
cells were pulsed for 2 hours with WT or CTBP1Q277R 25-mer peptide, followed by an 
overnight co-culture with CTBP1Q277R -TCR-transduced T cells. As indicated in Figure 3C, 
IFN-γ production was detected only when T cells were co-cultured with COS-7 cells 
transfected with HLA-DRA1*01:01:01 and HLA-DRB1*03:01:01, thus identifying them as 
the HLA restriction element for CTBP1Q277R-TCR.
Patient 2, a 39-year-old man with primary bladder cancer, had a single TURBT before 
presenting to the NIH with relapsed disease. Two consecutive tumor resections were 
performed, and TILs grew from only four out of 12 fragments obtained with the first 
procedure, and seven out of 12 fragments obtained with the second. A total of 232 unique 
mutations were identified by WES, which were then incorporated into 20 individual TMGs. 
After a co-culture with TMG-electroporated autologous DCs, two TILs from separate 
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resections (R1F4 and R2F1) exhibited marked IFN-γ production against TMG9, TMG11 
and TMG12 (Figure 4A). However, co-cultured TILs exhibited no significant 4–1BB 
upregulation in response to the cognate TMGs (data not shown), indicating that the 
frequency of reactive T cells was likely very low. Unfortunately, limited availability of 
samples precluded further experimentation and identification of the neoantigen-specific 
TCRs.
TILs from the remaining three patients exhibited no significant IFN-γ production following 
an overnight co-culture with neoantigen-loaded autologous EBV-B cells. Briefly, for Patient 
3, eight TIL cultures grew from 12 tumor fragments, and none demonstrated specific 
reactivity against EBV-B cells electroporated with TMGs (N=17) or pulsed with mutated 
peptide pools (N=17) encoding 194 tumor-specific mutations (Figure 4B). For Patient 4, 
four TIL cultures grew from 24 tumor fragments; no specific reactivity was observed against 
any of the TMGs (N=13) or mutated peptide pools (N=12) representing 142 mutations 
(Figure 4C). Finally, for Patient 5, two TIL cultures grew from 24 tumor fragments; no 
specific reactivity was seen against any of the TMGs (N=19) or mutated peptide pools 
(N=20) encoding a total of 230 cancer mutations (Figure 4D).
Discussion
In this study, we grew TILs from five patients with primary localized urothelial carcinoma of 
the bladder, including low and high-grade NMIBC and high-grade MIBC, and screened 
them for recognition of tumor-specific mutations. In our previous experience with screening 
TILs from patients with metastatic melanoma and gastrointestinal cancers, the majority of 
hits could be obtained from both screening against the mutated peptides and the TMGs. The 
peptide approach, however, showed a slight bias towards detecting CD4+ TIL responses, 
whereas the TMG approach slightly biased the detection towards the CD8+ TILs 
(unpublished data). To avoid such biases in this study, we utilized both approaches when 
screening TILs, whenever we had sufficient number of cells available.
We found that a CD4+ subset of TILs from Patient 1, who had high-grade NMIBC 
previously treated with BCG, specifically recognized a point mutation in CTBP1 protein 
(CTBP1Q277R). Furthermore, we isolated an HLA-DRB1*03:01-restricted, CTBP1Q277R-
reactive TCR and confirmed that it could recognize the mutant, but not the WT CTBP1 
peptide. CTBP1 is a transcriptional corepressor that plays a role in oncogenesis through 
suppression of genes that regulate cell cycle progression, DNA repair, apoptosis and 
intercellular adhesion (48). Although CTBP1 overexpression has previously been detected in 
several cancers, oncogenic repercussions of its mutations remain largely unknown. In 
addition, CTBP1 mutation at the amino acid position 277 has not been reported in the 
COSMIC (Catalogue of Somatic Mutations in Cancer) database, and thus appears to be 
unique to Patient 1.
Even though ICIs have previously been shown to elicit durable regressions of metastatic 
bladder tumors, identification of specific neoantigens has been lacking. Our study, 
conducted in patients with primary disease, shows that neoantigen-reactive TILs can be 
isolated from a bladder tumor specimen, a finding consistent with the previous evidence that 
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tumors express unique antigens can be recognized by T cells (49). Although a previous 
study found that circulating CD8+ T cells from a patient with primary bladder cancer 
recognized a tumor-specific point mutation in LPGAT1 (also known as KIAA0205), a 
ubiquitously expressed enzyme involved in membrane phospholipid metabolism, this 
reactivity arose from a circulating T cell clone after in vitro stimulation with irradiated 
tumor cells (50, 51). Thus, this T-cell clone might not necessarily represent T cells residing 
within the tumor.
Several technical challenges have limited our ability to discover additional neoantigens. The 
starting amount of tumor tissue was very modest and had been immersed in urine prior to 
excision. Tumor infiltration by T cells, as assessed by IHC for CD3, CD8 and CD4, was 
overall weak (Table 1) and could not readily explain the success rate in raising TIL cultures, 
likely because of the heterogeneity between the parts of primary tumors used for IHC and 
TIL culturing. In contrast to our previous studies of melanoma and gastrointestinal tumors, 
TIL growth was observed in only a fraction of plated tumor fragments (Table 1), which 
further limited the number and repertoire of cells available for testing. TIL growth occurred 
slowly, raising concerns that non-specific, bystander T cells may have outgrown the 
exhausted, neoantigen-reactive T cells in the long-term cultures (52). Lastly, as in the case of 
Patient 2, whose TILs exhibited significant IFN-γ production in response to three TMGs, 
the frequency of the potentially reactive T cells was likely too low to allow the detection by 
flow cytometry based on 4–1BB up-regulation, thereby precluding the possibility of further 
enrichment and testing of these T cells.
In addition to these limitations, tumor-intrinsic properties could have reduced our ability to 
identify neoantigen-reactive TILs in bladder cancer. The heterogeneity of primary bladder 
tumors, which could be more pronounced than in metastases, could have prevented the 
identification of TILs recognizing mutations unique to the parts of the tumor that were not 
captured by WES analysis of a limited tumor fragment. Additionally, several previous 
studies reported a high prevalence of partial or complete MHC class I molecule loss from 
primary bladder tumors (53–57), which could restrict the presentation of tumor neoantigens.
Tumor MHC expression in our study cohort was variable, as was the T cell infiltration 
(Table 1). The finding of a CTBP1Q277R-reactive CD4+ T cell clone from a tumor with 
seemingly undetectable MHC class II expression and sparse T cell infiltration highlights 
how tumor heterogeneity, well-described in primary bladder tumors (58), can limit the use of 
a single tumor biopsy in defining the biomarkers that could predict the sensitivity to 
immunotherapies. Accordingly, our finding could potentially help explain the lack of 
consistency in correlation between clinical benefits of immunotherapy and the tumor 
immune features in some circumstances.
It has been shown that CD4+ T cells can induce significant tumor regressions in cancer 
patients by targeting MHC class II-restricted cancer antigens (36, 59, 60). One important 
question is whether the tumor cells without detectable MHC class II expression can still be 
eliminated by the tumor antigen-reactive CD4+ T cells. Although previous work in a murine 
melanoma model suggested that tumor regressions occur following IFN-γ-mediated in vivo 
upregulation of MHC class II molecules on tumor cells (61, 62), further research is needed 
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to test whether this applies to human tumors. Alternatively, CD4+ T cells could recognize 
tumor antigens presented by antigen-presenting cells and then prime the immune responses 
against additional tumor antigens, some of which could be MHC class I-restricted - a 
phenomenon called “antigen spreading”(63). Again, further evidence is necessary to support 
this hypothesis in human cancer.
Due to its small size and the aforementioned technical limitations, our study cannot be used 
to accurately determine whether the neoantigen-specific T cells are significantly represented 
in the population of patients with bladder cancer, and whether they truly drive anti-tumor 
immune responses. To better address these questions, future studies would have to test a 
larger number of patients, especially patients with more advanced/metastatic disease, from 
which larger tumor specimens could be obtained. Alternatively, PD-1+ T cells from the 
peripheral blood could be screened in an attempt to identify cancer neoantigens, as 
previously reported in patients with metastatic melanoma (64). Further research will also be 
needed to determine the dynamics of neoantigen responses in patients with metastatic 
bladder cancer, and to explore the potential differences between those who responded to ICIs 
and those who were resistant.
In conclusion, we demonstrated that a cancer-specific CTBP1Q277R mutation elicited a 
TCR-mediated, MHC class II-restricted recognition by endogenous TILs. This proof-of-
principle study provides preliminary evidence that neoantigen-reactive TILs can be isolated 
from bladder tumors, which in turn may offer a mechanistic insight into the effectiveness of 
immune checkpoint inhibition in bladder cancer treatment. Furthermore, our findings 
provide a preliminary rationale for future use of adoptively transferred neoantigen-reactive T 
cells in the treatment of patients with bladder cancer. This could be accomplished either by 
expanding and administering TILs that specifically recognized cancer neoantigens, as 
previously reported by our group, or by isolating the neoantigen-reactive TCRs and 
transferring them into autologous PBMCs, which would then be infused back to the patients 
(32, 65).
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1. Tumor-infiltrating lymphocytes (TILs) can be grown from primary bladder 
tumors.
2. Neoantigen-reactive TILs can be isolated from a bladder tumor specimen.
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Figure 1. TILs grown from Patient 1 recognized tumor-specific CTBP1Q277R mutation.
(A) Four TILs (F1–4) were co-cultured with autologous EBV-B cells electroporated with 11 
TMGs encoding tumor-specific mutations, or with sterile water alone (Mock). Following an 
overnight incubation, IFN-γ concentration in co-culture supernatants was determined by 
IFN-γ ELISA. (B and C) F3 TILs were co-cultured with EBV-B cells pulsed overnight with 
individual 25-mer peptides encoded in TMG2, followed by IFN-γ ELISA (B) and with wild-
type and mutant CTBP1 25-mer, followed by a multiplex assay for IFN-γ, TNF-α, IL-4, 
IL-5, IL-10, IL-13 and GM-CSF (C). All the experiments were performed once owing to a 
limited number of available TILs. Bars represent average reads from two duplicate wells; 
error bars represent SD.
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Figure 2. A TCR isolated from CTBP1Q277R-reactive TILs recognized CTBP1Q277R.
(A) F3 TILs were co-cultured overnight with EBV-B cells pulsed with CTBP1Q277R 25-mer 
peptide, followed by FACS sorting based on 4–1BB upregulation. Contour plots indicate the 
percentage of CD4+ 4–1BB+ lymphocytes in the respective co-cultures; graphs were gated 
on all live lymphocytes. (B) CTBP1Q277R-TCR CDR3 sequence, as identified by single-cell 
RNA sequencing. (C) Transduction efficiencies for CTBP1Q277R-TCR, as assessed by flow 
cytometry for mouse TCR-β constant chain (mTCR-β) expression. Histograms depict 
mTCRβ staining on untransduced (shaded) and transduced (unshaded) cells from two 
donors; numbers (%) indicate the estimated transduction efficiency. Graphs were gated on 
all live lymphocytes. (D) CTBP1Q277R-TCR-transduced T cells from (C) were co-cultured 
with autologous EBV-B cells pulsed overnight with serial dilutions of either wild type (WT) 
or CTBP1Q277R peptide (MUT). IFN-γ concentration was measured in co-culture 
supernatants by ELISA. A representative of two independently performed experiments is 
shown. (E) CTBP1Q277R-TCR transduced CD4+ cells from the same donors were co-
cultured overnight with EBV-B cells stimulated with 10 μM WT or MUT peptide; 
concentrations of multiple cytokines in the co-culture supernatants were analyzed for a 
multiplex assay. Data represents average reads from two duplicate co-culture wells; error 
bars represent SD.
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Figure 3. Determination of minimal epitope and HLA restriction element for CTBP1Q277R-
TCR.
(A) CTBP1Q277R-TCR-transduced T cells were co-cultured with autologous EBV-B cells 
pulsed with serial two-amino acid truncations of CTBP1Q277R 25-mer. IFN-γ concentration 
was determined by ELISA. Top 6 sequences on the y axis represent truncations from the C-
terminus, and the bottom 6 from the N-terminus of CTBP1Q277R 25-mer. Grayed area 
highlights the Q277R mutation; underlined amino acids delineate the potential minimal 
epitope. (B) Transduced T cells were co-cultured with autologous EBV-B cells pulsed with 
CTBP1Q277R 25-mer, 13-mer identified in (A), and three additional truncations of the latter 
(white dots). Corresponding WT peptides were used as a control (black dots). IFN-γ 
concentration was determined by ELISA. (C) COS-7 cells, transfected with combinations of 
plasmids encoding all paired MHC class II molecules identified in Patient 1, were pulsed for 
2 hours with WT or CTBP1Q277R (MUT) peptide and co-cultured with CTBP1Q277R-TCR-
transduced T cells. Results of IFN-γ ELISA are shown. For (A-C), a representative of two 
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independent experiments is shown. Data represents average reads from two duplicate co-
culture wells; error bars represent SD.
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Figure 4. TILs from Patient 2 recognized autologous DCs electroporated with TMG 9, 11 and 12, 
whereas TILs from the remaining patients did not recognize any mutations.
(A) Eleven TILs from Patient 2 (R1F1-R1F7 from the first and R2F1-R2F4 from second 
tumor resection) were co-cultured with autologous DCs electroporated with 20 TMGs 
encoding tumor-specific mutations, or with sterile water alone (Mock). (B-D) TILs from 
Patient 3 (B), 4 (C) and 5 (D) were co-cultured with autologous EBV-B cells that were either 
electroporated with TMGs encoding tumor-specific mutations (upper panels) or pulsed with 
peptide pools (PP) encoding the same mutations (lower panels). IFN-γ concentration was 
determined in co-culture supernatants using IFN-γ ELISA. In (D), PBMCs transduced with 
MAGE-A3 TCR were co-cultured with cognate EBV-B cells electroporated with MAGE-A3 
RNA and used as a positive control. All the experiments were performed once owing to a 
limited number of available TILs. CSC = cell stimulation cocktail.
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